STOCK TITAN
  1. Home
  2. News
  3. NNVC

NanoViricides Inc. - NNVC STOCK NEWS

Welcome to our dedicated page for NanoViricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on NanoViricides stock.

NanoViricides Inc. (NYSE American: NNVC) is a pioneering nano-biopharmaceutical company dedicated to the discovery, development, and commercialization of antiviral drugs targeting life-threatening viral infections. Utilizing advanced nanomedicine technologies, NanoViricides focuses on creating nanoviricide® drug candidates designed to attack and dismantle virus particles.

The company's diverse product pipeline includes:

  • HerpeCide™ Program: Dermal topical and eye drops for treating shingles, post-herpetic neuralgia (PHN), chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis.
  • FluCide™: Broad-spectrum anti-influenza nanoviricide, available in injectable form for hospitalized patients and oral form for outpatients.
  • DengueCide™: Treatment for all types of dengue viruses.
  • HIVCide™: An escape-resistant anti-HIV nanoviricide.

One of NanoViricides' lead candidates, NV-387, has shown promising results against a wide range of viruses, including RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and smallpox/monkeypox. NV-387 has progressed to Phase II clinical trials for RSV treatment, having completed Phase I trials with no adverse events.

The company’s innovative technology platform mimics host-side features that viruses use to enter cells, making it unlikely for viruses to evade these drugs even with mutations. This breakthrough approach has resulted in NV-387 demonstrating superior efficacy compared to existing approved drugs in preclinical studies.

Financially, NanoViricides reported a cash balance of approximately $3.51 million as of March 31, 2024, with additional agreements bringing the total available cash to approximately $6 million. Despite facing challenges in clinical trials due to the waning COVID-19 pandemic, the company remains focused on advancing its pipeline, securing additional financing, and exploring partnerships to support its operations.

Recent news highlights significant progress with NV-387, including strong activity against various viruses, successful preclinical and clinical trial outcomes, and plans for further development. NanoViricides continues to drive innovation in antiviral therapy, aiming to meet unmet medical needs and revolutionize the treatment of viral infections.

News

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

Rhea-AI Summary
NanoViricides, Inc. (NNVC) successfully completed the Phase 1a/1b Clinical Trial of NV-CoV-2, reporting no adverse events. NV-387, the active ingredient, demonstrated excellent safety and broad-spectrum antiviral activity. The results indicate a promising potential for rapid response to pandemics and treatment of viral infections. The trial was managed by Karveer Meditech Pvt. Ltd. in India and conducted at Mahatma Gandhi Mission's Medical College & Hospital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.35%
Tags
clinical trial
-
News

NanoViricides to Present at the Biotech Showcase in San Fransisco

Rhea-AI Summary
NanoViricides, Inc. (NNVC) to present at Biotech Showcase 2024, highlighting successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies drug products containing the novel antiviral nanomachine NV-387, with broad-spectrum antiviral activity across multiple virus families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
conferences
-
News

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

Rhea-AI Summary
NanoViricides, Inc. (NNVC) reported the successful completion of the Single-Ascending Dose part of the Phase 1a/1b Human Clinical Trial of NV-CoV-2, a broad-spectrum antiviral drug. The drug contains the nanoviricide active agent, NV-387, which has shown strong antiviral activity against coronaviruses, RSV, and Smallpox. The Phase 1a trial in healthy volunteers was completed with no adverse events found. Recruitment for the Multiple-Ascending Dose part was also completed. NV-387 has shown broad-spectrum antiviral activity across multiple virus families, addressing an unmet medical need for a safe and effective antiviral drug. The drug has the potential to revolutionize antiviral treatment and addresses large market sizes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.73%
Tags
earnings clinical trial
News

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

Rhea-AI Summary
NanoViricides, Inc. (NYSE American: NNVC) - Quarterly Report on Form 10-Q filed, Financial Status, Liquidity Improvement, Drug Pipeline, Platform Technology Expansion, and Market Potential
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.7%
Tags
clinical trial
-
News

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development

Rhea-AI Summary
NanoViricides, Inc. (AMEX:NNVC) reports that its broad-spectrum antiviral drug candidate, NV-387, was highly effective in an animal model for MPox and Smallpox virus infections. NV-387, currently in Phase 1a/1b human clinical trials for COVID-19 indication in India, has shown strong activity against Seasonal Coronaviruses, SARS-CoV-2, and Respiratory Syncytial Virus (RSV). The drug is designed to mimic a host cell membrane bearing 'Sulfated Proteoglycans' ('S-PG') family of virus attachment receptors, providing a broad spectrum of antiviral activity. Oral NV-387 treatment led to a significant increase in survival lifespan in animal models, indicating its relative effectiveness compared to other drugs. The company believes that NV-387 has the potential to revolutionize the fight against viruses, similar to how antibiotics revolutionized the fight against bacterial infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.67%
Tags
clinical trial
-
News

NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET

Rhea-AI Summary
NanoViricides to present at PODD Conference and highlights the potential of its antiviral drug candidate NV-387
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
partnership conferences
News

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides

Rhea-AI Summary
NanoViricides reports successful progress in Phase 1a/1b clinical trial of NV-CoV-2 antiviral drug
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
clinical trial
-
News

Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides

Rhea-AI Summary
NanoViricides, Inc. reports strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV. NV-387 is expected to advance into Phase II human clinical trials for RSV treatment, which will significantly speed up the development of the RSV drug, save costs, and improve ROI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.64%
Tags
none
-
News

Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
clinical trial
News

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
clinical trial

FAQ

What is the current stock price of NanoViricides (NNVC)?

The current stock price of NanoViricides (NNVC) is $1.28 as of November 21, 2024.

What is the market cap of NanoViricides (NNVC)?

The market cap of NanoViricides (NNVC) is approximately 17.9M.

What does NanoViricides Inc. specialize in?

NanoViricides Inc. specializes in discovering, developing, and commercializing drugs for the treatment of viral infections using advanced nanomedicine technologies.

What are the key products in NanoViricides' pipeline?

Key products include HerpeCide™ for herpes-related conditions, FluCide™ for influenza, DengueCide™ for dengue viruses, HIVCide™ for HIV, and NV-387 for various viral infections including RSV, COVID-19, and Influenza.

What recent advancements has NanoViricides made?

Recent advancements include NV-387 demonstrating strong antiviral activity, progressing to Phase II clinical trials for RSV, and showing superior efficacy in preclinical studies compared to existing drugs.

How does NanoViricides' technology work?

Their nanoviricide® drug candidates are designed to mimic host-side features that viruses use to enter cells, making it difficult for the viruses to escape even with mutations.

What financial position was reported by NanoViricides?

As of March 31, 2024, NanoViricides reported a cash balance of approximately $3.51 million, with additional agreements bringing the total available cash to approximately $6 million.

What is NV-387?

NV-387 is a broad-spectrum antiviral drug candidate that has shown strong activity against viruses like RSV, COVID-19, Influenza A, and smallpox/monkeypox. It has completed Phase I trials and is advancing to Phase II.

What is unique about NanoViricides' approach to antiviral therapy?

NanoViricides uses a host-mimetic technology platform that mimics the features viruses use to bind and enter cells, making it highly unlikely for viruses to escape the nanoviricide drugs even with mutations.

Who are NanoViricides' key partners?

NanoViricides collaborates with various external collaborators and consultants, and licenses its technology from TheraCour Pharma Inc. for specific viruses.

How is NanoViricides addressing the COVID-19 pandemic?

NanoViricides has developed NV-387 as a broad-spectrum antiviral with strong activity against COVID-19. Although clinical trials for COVID-19 treatment faced challenges due to the waning pandemic, the company continues to seek non-dilutive funding and focus on further development.

What are the challenges faced by NanoViricides in drug development?

The company faces typical drug development challenges including lengthy processes, substantial capital requirements, and dependence on external collaborators and consultants. Ensuring safety and efficacy in clinical trials remains a critical focus.

Stock NNVC logo
NanoViricides Inc.

NYSE:NNVC

NNVC Rankings

#5330 Ranked by Market Cap
N/A Ranked by Dividends

NNVC Stock Data

17.85M
13.78M
3.95%
9.42%
2.43%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SHELTON